

15th John Vane Memorial Symposium on Prostacyclin Science & Pulmonary Vascular Disease

Faculty Chair

Chris Thiemermann, Queen Mary University of London, UK

Session Chairs

Paul Corris, University of Newcastle, UK

Michele D'Alto, University of Campania Luigi Vanvitelli, Caserta, Italy

James Klinger, Brown University, Providence, Rhode Island, USA

Irene Lang, Medical University of Vienna, Austria

Vallerie McLaughlin, University of Michigan, Ann Arbor, USA

Nick Morrell, University of Cambridge, UK

Robert Naeije, Universite Libre de Bruxelles, Belgium

Ioana Preston, Tufts University School of Medicine, Boston, USA

Rajan Saggarr, University of California, Los Angeles, USA

Olivier Sitbon, Université Paris-Sud, France

Brendan Whittle, Queen Mary University of London, UK

20th & 21th March 2020

The Royal Society

6-9 Carlton House Terrace, London, SW1Y 5AG, UK

CPD accreditation: TBC

Friday, 20th March 2020

- 08.15- 09.15** Registration, tea and coffee
- 09.15** Welcome
Chris Thiemermann, Queen Mary University of London, UK
-

Session I

- Chairs:** Chris Thiemermann
Brendan Whittle
- 09.30** Polyamines and PAH
Nick Morrell, University of Cambridge, UK
- 10.00** Prostacyclin analogs and non-vasodilator effects: is there any antithrombotic effect in PAH
David Smadja, Paris Descartes University/European Georges Pompidou Hospital, Paris, France
- 10.30** Noval target for pulmonary hypertension – the zinc transporter ZIP12
Lan Zhao, Imperial College London, UK
- 11.00** Refreshments
-

Session II

- Chairs:** Michele D'Alto
Olivier Sitbon
- 11.30** Risk Stratification and Medical Therapy for PAH
Vallerie McLaughlin, University of Michigan, Ann Arbor, USA
- 12.00** Anti-cytokine therapy in PAH
Mark Toshner, University of Cambridge, UK
- 12.30** Lunch
-

Session III

- Chairs:** James Klinger
Ioana Preston
- 14.00** Topical cannabinoids to reduce pain for subcutaneous administration of prostacyclins
Rajan Saggar, University of California, Los Angeles, USA
- 14.30** Afterload reduction in the early use of prostacyclin (or MPAP21-24: Should we treat it?)
Roberto Badagliacca, Sapienza University of Rome, Italy
- 15.00** Non-invasive methods to assess PAH
Robert Naeije, Universite Libre de Bruxelles, Belgium
- 15.30** Refreshments
-

Session IV

- Chairs:** Robert Naeije
Irene Lang
- 16.00** Palliative care in PAH
Sarah Woolcock, Newcastle University, UK
- 16.30** Emerging Endpoints in PAH
Olivier Sitbon, Université Paris-Sud, France
- 17.00-18.30** Meeting adjournment and Evening Reception at the Royal Society

Saturday, 21th March 2020

08.00-09.30 Tea and coffee

Session V

Chairs: **Paul Corris**
Rajan Saggar

09.30 Risk reduction and right heart reverse remodelling by upfront triple combination therapy in PAH
Michele D'Alto, University of Campania Luigi Vanvitelli, Caserta, Italy

10.00 Novel endpoints in clinical trial design in PAH
Ioana Preston, Tufts University School of Medicine, Boston, USA

10.30 Prostacyclins to protect Ischemia and reperfusion injury of organs for transplantation
Raman Venkataramanan, University of Pittsburg, USA

11.00 Refreshments

Session VI

Chairs: **Nick Morrell**
Vallerie McLaughlin

11.30 Advances in Balloon Pulmonary Angioplasty for the treatment of non operable CTEPH
Irene Lang, Medical University of Vienna, Austria

12.00 Mesenchymal Stem Cell Extracellular Vesicles for the Treatment of Pulmonary Hypertension
James Klinger, Brown University, Providence, Rhode Island, USA

12.30 Pulmonary Hypertension in chronic lung disease
Steven D. Nathan, Inova Fairfax Hospital, Falls Church, USA

13.00 Lunch

14.00 Close of meeting